Affinity Asset Advisors LLC acquired a new position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) during the 2nd quarter, Holdings Channel reports. The firm acquired 900,000 shares of the company’s stock, valued at approximately $9,090,000. Nautilus Biotechnology accounts for about 3.3% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 4th biggest position.
Other hedge funds have also bought and sold shares of the company. Penserra Capital Management LLC acquired a new position in Nautilus Biotechnology during the 2nd quarter valued at approximately $48,000. Magnetar Financial LLC acquired a new position in Nautilus Biotechnology during the 2nd quarter worth $108,000. Lombard Odier Asset Management USA Corp acquired a new position in Nautilus Biotechnology during the 2nd quarter worth $505,000. Geode Capital Management LLC acquired a new position in Nautilus Biotechnology during the 2nd quarter worth $660,000. Finally, Franklin Resources Inc. acquired a new position in Nautilus Biotechnology during the 2nd quarter worth $5,050,000. Institutional investors own 26.60% of the company’s stock.
In other news, Director Matthew S. Mcilwain purchased 13,568 shares of the business’s stock in a transaction on Tuesday, August 24th. The stock was purchased at an average price of $7.68 per share, with a total value of $104,202.24. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Anna Mowry purchased 17,500 shares of the business’s stock in a transaction on Thursday, August 12th. The stock was purchased at an average cost of $7.71 per share, with a total value of $134,925.00. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 47,777 shares of company stock valued at $367,204.
Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Monday, August 9th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.12). As a group, sell-side analysts anticipate that Nautilus Biotechnology, Inc. will post -0.38 earnings per share for the current year.
NAUT has been the subject of several research analyst reports. The Goldman Sachs Group initiated coverage on Nautilus Biotechnology in a report on Wednesday, August 4th. They issued a “neutral” rating and a $10.00 price objective for the company. Jefferies Financial Group initiated coverage on Nautilus Biotechnology in a research report on Tuesday, July 13th. They set a “buy” rating and a $13.00 target price on the stock.
Nautilus Biotechnology Company Profile
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating platform technology for quantifying and unlocking the complexity of the proteome. It operates Nautilus Proteomic Analysis Platform, an integrated single-molecule protein analysis platform that leverages a nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis to potentially identify and quantify the proteome.
Further Reading: Why is cost of goods sold important?
Want to see what other hedge funds are holding NAUT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nautilus Biotechnology, Inc. (NASDAQ:NAUT).
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.